Slingshot members are tracking this event:

Gilead Sciences (GILD) plans to fully enroll Phase 3 STELLAR 4 trial for nonalcoholic steatohepatitis (NASH) evaluating selonsertib in treating F4 cirrhosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GILD Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 23, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nash Cirrhosis, Selonsertib, Phase 3, Stellar Trial